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Abstract  
 A case report will be presented of patient with type 2 diabetes. She treats her diabetes 
with a single oral drug, metformin. This is a common scenario for primary care providers. 
Metformin is a frontline treatment for type 2 diabetes. Many sources have linked a higher 
incidence of cancer in patients with diabetes. The combination of these two aspects could 
lead to an exciting new development in the treatment of cancer. What if metformin is 
chemotherapeutic? That means that it may be able to be used as an adjunct therapy to 
current chemotherapy regimens to decrease the risk of mortality from cancer. This paper 
will examine a variety of studies that has linked metformin to a decrease in mortality 
from a variety of cancers; including, but not limited to, breast, prostate, lung, and 
colorectal cancers. The repurposing of a safe and inexpensive drug such as metformin in 
the fight against cancer has exciting and promising results. This could have positive 
results for patients without type 2 diabetes as well, as they could benefit from metformin 
therapy for cancer mortality prevention. Metformin may be beneficial for patients for 
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Background 
 More than 29 million people in the United States have diabetes (CDC, 2014). Of those 29 
million, 90-95% have type 2 diabetes (CDC, 2016). Type 2 diabetes is more common in adults. 
Specific risk factors for type 2 diabetes include obesity, sedentary lifestyle, family history, and a 
history of gestational diabetes. It is a disease of insulin resistance, hyperglycemia, and impaired 
insulin secretion. There are a variety of medication regimens available for patients with type 2 
diabetes. These include biguanides, sulfonylureas, glucagon-like peptide-1 (GLP-2) agonists, 
alpha-glucosidase inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, and insulin.  
 Metformin is the frontline treatment for type 2 diabetes. It is the only available bigunaide. 
It is safe, effective, and affordable. It is usually well tolerated in patients. However, it does have 
a high incidence of gastrointestinal disturbance. This can be minimized or prevented by starting 
at a low dose and titrating to the goal dosage. The medication should also be taken with food. It 
is contraindicated in chronic kidney disease. It can also be beneficial for patients with 
prediabetes, gestational diabetes, metabolic syndrome, and polycystic ovarian syndrome. 
Research has begun to study the effects of metformin on cancer progression and mortality. This 
is called drug repurposing. It is a method to save time and money by studying a drug that has 
already been extensively researched, developed, and deemed safe.  
 As diabetes is such a common disorder, it is often seen in primary care settings. The 
following case report is a recheck of a patient with known type 2 diabetes. These patients require 
frequent follow up and management. Although this patient’s glucose is in the normal range, her 
hemoglobin A1C (HbA1C) is out of the ideal range for a diabetic. The goal for an otherwise 
healthy type 2 diabetic is a goal HbA1C under 7.0 percent. HbA1C is a measurement of the red 
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blood cell’s exposure to glucose over the course of three months. The free glucose in the blood 
binds irreversibly to the hemoglobin in the red blood cell. That is why it is able to be measured 
throughout the life of the red blood cell. The patient is currently only on a low dose of metformin 
to control her type 2 diabetes. Since she is able to tolerate the medication well, she is a great 
candidate for increasing the metformin for better glucose control. As discussed earlier, 
metformin may have a cancer protectant component as well.  
Case Report 
 A 60-year-old women presents to the clinic for a recheck of her type 2 diabetes mellitus. 
She was first diagnosed with diabetes 10 years ago with after routine lab work found she had an 
elevated fasting blood glucose. She then had a hemoglobin A1C drawn, which confirmed the 
diagnoses of diabetes. She also has a history of hypertension and hyperlipidemia, for which she 
is on medication. 
She grew up in rural North Dakota. Both of her parents had type 2 diabetes and heart 
disease. She has a younger brother. He is in good health. She has never used tobacco products. 
She drinks alcohol 2-3 times per week. She usually drinks about 3 light beers per time.  
She has been controlling her diabetes with Metformin monotherapy, with reported 
“good” control of her diabetes. She denies any adverse effects of the medication. She has met 
with a Diabetic educator in the past and found this helpful. She does not check her blood sugars 
at home. She does try to eat a low carbohydrate, high protein diet, although she admits she has a 
sweet tooth and enjoys treats. She has not been exercising regularly. She does get yearly 
ophthalmological exams. Her ophthalmologist is aware of her diabetic diagnosis. She sees her 
dentist every six months.  
Exam and Treatment 
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 The patient’s physical exam is unremarkable. Heart has a regular rate and rhythm with no 
abnormal heart sounds noted. Lungs are clear to auscultation. Patient denies any numbness or 
tingling to the hands or feet. The patient’s feet are slightly dry, but skin is intact with no callous 
formation. Monofilament exam is within normal limits. 
 Her blood pressure is elevated at 148/98. She has checked her blood pressure at the 
drugstore recently, and states it was “normal”. Recent lab works shows an elevated HbA1C of 
8.5%. Three months ago, the patient’s hemoglobin A1C was 8.2%. Her fasting blood glucose is 
within normal limits of 96 mg/dl. Her total lipids are elevated at 209 mg/dl with a low HDL of 31 
mg/dl and a high LDL of 95 mg/dl. Her triglycerides are also elevated at 184 mg/dl. Her complete 
blood count and basic metabolic panel are all within normal limits. 
 The patient does think that her elevated HgA1c could be due in part to eating more sweets. 
She is scheduled to meet with a diabetic educator next week. She does think that this will help get 
herself “on track” with her dietary choices. She also believes that she will be able to increase her 
physical activity as the weather improves. We also discussed her medication options. Medications 
discussed included insulin, injectable antihyperglycemic medication, and other classes of oral 
antihyperglycemic drugs. Since the patient is only on a low dose of metformin and the medication 
is well tolerated, the decision was made to increase her metformin. We did discuss that with an 
increase in metformin there is a higher probability of having adverse side effects, such as 
abdominal symptoms. The patient agrees to increasing her dosage of metformin to 1000 mg twice 
daily, with breakfast and supper. She will contact the clinic if she has any adverse effects. We 
discussed the possibility of switching to the long acting metformin to help decrease any adverse 
effects, if they occur. She will return to the clinic in three months for lab work and a recheck of 
her diabetes. We did not increase her Lisinopril dosage at this time. The patient will return to the 
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clinic twice this week for blood pressure checks. If her blood pressure remains over her goal of 
130/80, we will increase her Lisinopril. The patient is agreeable to this plan.  
Review of Literature 
Rationale 
Metformin is a biguanide that was first discovered in 1922. It was introduced as a 
medication in 1957 in France. Due to complications and further studies, it was not available for 
use in type 2 diabetes mellitus in the United States until 1994 (Diabetes Net, 2014). Biguanides 
are a class of antihyperglycemics that improve peripheral glucose uptake, intracellular insulin 
sensitivity, inhibits gluconeogenesis, and decreases intestinal absorption of glucose. Metformin 
is the only approved and available bigaunide.  
Metformin use may be contraindicated in patients with renal disease. According to 
UpToDate (2017), glomerular filtration rate (GFR) should be greater than 45 mL/min when 
initiating therapy. If the GFR is between 30-45 mL/min therapy should be reconsidered or a 
decreased dosage may be necessary (UpToDate, 2017). However, according to Chamberlain et 
al. (2017), the American Diabetes Association (ADA) states that therapy can be initiated with a 
GFR as low as 30 mL/min. Glomerular filtration rate should be monitored more frequently in 
patients with GFR less than 60 mL/min, every 3-6 months is the recommendation (UpToDate, 
2017). 
Metformin is usually well tolerated by patients, however, gastrointestinal side effects can 
deter patients from use. This can be improved when patients start at a low dose take and take the 
medication with a full meal. If the low dose is tolerated, the dose can be titrated up for better 
glycemic control. The extended release form is associated with a decrease in gastrointestinal side 
effects (UpToDate, 2017). 
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Currently, metformin is the first-line treatment for treatment of type 2 diabetes by the 
ADA (Chamberlain et al., 2017). It is safe, effective, and inexpensive. Metformin has also been 
repurposed into off-label uses. Metformin has also been studied for off-label use in the 
prevention of type 2 diabetes in prediabetics, metabolic syndrome, gestational diabetes, and 
polycystic ovarian syndrome (UpToDate, 2017). Current research shows that it may also be 
beneficial for the use in decreasing the risk of cancer mortality. 
Synthesis of Evidence 
 Hatoum and McGowan said “Cancer and diabetes are two of the most common chronic 
diseases worldwide, with a strong association between the two diseases (pp 1, 2014).” Many type 
2 diabetics are on metformin. Therefore, studies to repurpose a drug like metformin to help with 
the prevention or decrease the mortality of cancer is extremely important. Drug repurposing can 
cut cost and expedite the process of delivering new drugs to market. Developing a new drug can 
cost upwards of $800 million and take up to 17 years of testing (Xu et al., 2014). Does this mean 
that metformin can be repurposed as a chemotherapeutic agent? 
 Much of the research related to metformin and cancer mortality rates are retrospective, 
meta-analysis studies. In the study by Xu et al. (2014), a meta-analysis of electronic health 
records (EHRs) from Vanderbilt and Mayo Clinic were examined to determine if diabetic 
patients taking metformin had a decreased mortality rate from cancer. The study consisted of 4 
groups of patients with cancer: type 2 diabetics on metformin, type 2 diabetics on oral 
medications other than metformin, type 2 diabetics on insulin only, and non-diabetic patients (Xu 
et al., 2014). This study found that the impact of metformin on mortality was dependent on the 
type of cancer. There was statistically significant data to show that the mortality from cancer was 
decreased in patients with breast, colorectal, lung, or breast cancer (Xu et al., 2014). In the study 
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by Tang et al. (2017), the mortality from cancer was found to be less in patients on metformin 
than patients without diabetes. 
 A study by Lin et al. (2015) used Medicare’s Surveillance, Epidemiology, and End 
Results (SEER) registry to compare the overall survival of diabetic individuals age 65-79 with 
stage IV lung cancer. This study found that diabetics who took metformin lived an average of 5 
months after diagnosis, compared to only 3 months for patients on other antidiabetic medications 
(Lin et al., 2015). This suggests that the effect of improved survival is related specifically to 
metformin (Lin et al., 2015). 
 It is not fully understood how metformin decreases the progression and mortality from 
cancer. Gao et al. (2014) studied mice with breast tumors. The control group was untreated and 
the experimental group was treated with metformin. The mice were only studied for 15 days and 
breast tumor progression was not stopped. However, the breast tumors in the metformin treated 
group showed necrosis and decreased vascularity (Gao et al., 2014). The hypothesis that 
metformin can inhibit cancer cells is supported in the retrospective study by Heckman-Stoddard 
et al. (2015). This study gives two plausible ways how metformin may contribute to anti-
neoplastic activity. The insulin-lowering aspect of metformin may slow tumor proliferation in 
hyperinsulinemic patients (Heckman-Stoddard et al., 2015). This is linked to the cancer cell’s 
ability to proliferate unregulated. According to Hatoum and McGowan, “One of the hallmarks of 
cancer is the reprogramming of energy metabolism to fuel cancer cell growth and division 
(2014).” In diabetes, glucose is inefficiently processed which leads to hyperglycemia and 
hyperinsulinemia. The elevation in released insulin can lead to insulin resistance and pancreatic 
fatigue. Metformin increases glucose reuptake and decreases gluconeogenesis, thus leaving less 
intracellular glucose available for cancer cells.  
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Another proposed way that metformin slows the progression of cancer is by changing the 
makeup of the cancer cell. Metformin may suppress adenosine triphosphate (ATP) production by 
inhibiting the formation of the mitochondrial complex (Heckman-Stoddard et al., 2015; Wang et 
al., 2016). Specifically, it seems as though metformin blocks the respiratory capacity of the 
mitochondria (Wu et al., 2016). Disrupting the respiratory capacity of the mitochondria lowers 
the membrane potential of the cell. This results in increased autophagy of the proliferating cancer 
cell (Wang et al., 2016). The autophagy is induced when the biological pathway between the 
mitochrondria, nuclear pore complex, and acyl-CoA dehydrogenase family member 10 is 
destroyed (Wu et al., 2016). This disruption results into a malformation of the cell that makes it 
unable to grow or proliferate. Metformin may also indirectly effect the growth and proliferation 
of tumor cells by inhibiting liver gluconeogenesis (Tang et al., 2017). The inhibition of 
gluconeogenesis decreases insulin levels and hyperglycemia, which slows tumor growth and 
proliferation by robbing the cells of their energy source.  
Does metformin only restrict growth and proliferation of cancer cells? In a study by Han 
et al. (2017), metformin use was studied in preventing the recurrence of colorectal adenoma. 
This was a relatively small, retrospective study. Colorectal adenoma is the precursor to colorectal 
cancer. Colorectal adenoma are found on colonoscopy. Previous studies have shown a positive 
relationship between non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 
(Cox-2) inhibitors and colorectal adenoma prevention. However, these medications have 
increased risk of gastrointestinal bleeding and cardiovascular complications (Han et al., 2017). 
Therefore, NSAIDs and Cox-2 inhibitors are only used on a case to case basis in patients with a 
high risk for colorectal cancers (Han et al., 2017). Metformin was chosen in this study as a safer 
alternative due to its positive feedback and safety profile in previous studies. The study by Han 
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et al. (2017) did find that the study group on metformin did have a lower recurrence of total 
adenoma. The study did not find a significant difference in the recurrence of advanced adenomas 
(Han et al., 2017). Even with the varying results, the authors did theorize that metformin may be 
useful in suppressing the early adenoma to carcinoma sequence (Han et al., 2017). A larger 
cohort study with more long-term surveillance could confirm the effect of metformin on 
advancement of colorectal adenoma to colorectal cancer.  
Does this mean that all patients should be on metformin, regardless of a diagnosis of type 
2 diabetes? The studies examined agree that more research needs to be done for this to be 
approved by the Federal Drug Administration (FDA). The FDA considers metformin 
investigational in the treatment of breast cancer (Hatoum & McGowan, 2014). The safety of 
metformin for the comorbidities of cancer and the suitability of metformin as a treatment for 
cancer in patients without diabetes still needs to be studied and approved (Hatoum & McGowan, 
2014).  
Practice Recommendations 
 The American Family Physician’s Strength of Recommendation Taxonomy (SORT) was 
utilized to determine the strength of the recommendation of the benefit of metformin on cancer 
prevention and decreasing mortality. SORT uses a grading system of A-C to determine the 
quality of evidence, thus the validity of the evidence provided (Ebell et al., 2004). The following 
two practice recommendations will be graded using this method. 
 The studies examined in this literature review were primarily retrospective studies when 
human subjects were involved. Two of the studies were in vivo and included studying mice 
infected with cancerous cells and tumors. However, all of the studies did find the same results. 
Metformin use does decrease the risk of cancer mortality. The retrospective studies were all 
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under 10 years and would need more follow-up time for a stronger recommendation (Krader, 
2015). Using the SORT guideline, this gives this recommendation a B rating.  
Learning Points 
 Metformin is the frontline treatment for type 2 diabetes. It has many benefits. It lowers 
blood glucose with a low risk of hypoglycemia. It can protect the pancreas from fatigue and 
makes cells more susceptible to glucose. Unless the patient has a comorbidity, such as kidney 
failure, or is unable to tolerate metformin, type 2 diabetics should be on metformin. 
 Metformin may be repurposed to prevent and decrease mortality from a variety of 
cancers. Patients with diabetes are at an increased risk for cancer. With metformin, their risk of 
mortality from cancer may be decreased to less than a patient without diabetes.  
 In the future, patients with an increased risk for cancer or even those that are otherwise 
healthy may benefit from metformin. This is still in the investigational phase by the FDA. 
However, it has shown promise. Since this would be repurposing of an old drug, the approval 
may be faster and cheaper than developing a brand new drug with similar goals. 
Conclusion 
 A variety of medications are approved for use in type 2 diabetes. Metformin is the first 
choice treatment for diabetes in type 2 diabetics. Metformin is a safe, effective, and affordable 
medication. Although it is only approved for use in type 2 diabetes, it may also be useful in 
cancer prevention and decreasing the mortality from cancer. This has the potential to be a great 
example of drug-repurposing. It would save the expense and time of formulating, testing, and 
approving a brand new drug that could have similar effects. Larger, longer studies are still 
needed to determine a stronger correlation between metformin and cancer prevention. However, 
the initial results are very promising. 
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